MANAGEMENT

Daniel O’Connell, Chief Executive Officer

Dan O’Connell has over 20 years of venture creation, venture investment and start-up operations experience. He has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc since December 2014. Mr. O’Connell previously co-founded and served as CEO of Functional NeuroModulation Ltd. (FNM), a company developing implanted deep brain stimulation (DBS) therapies for Alzheimer’s. He led FNM company formation, secured funding of $13.4 million, established a strategic partnership with Medtronic, and recruited an experienced clinical operations team. Under his leadership, FNM initiated and completed enrollment for the ADvance Study, a randomized Phase 2 study of DBS in early AD which is serving as the basis for launching a global Phase 3 study in 2019.

Mr. O’Connell is a founding member and managing partner of NeuroVentures, a specialty venture firm he helped establish in 2001. His NeuroVentures investment and board involvement includes Acumen, BrainCells Inc., Concentric Medical Inc. (sold to Stryker, 2011), Cyberkinetics Inc., Kadmus Pharmaceuticals, Inc. (sold to Schering AG, 2007), NeurAxon Inc., Saegis Pharmaceuticals, Inc. (sold to Lundbeck A/S, 2007), Setagon Inc. (sold to Medtronic, 2007). Mr. O’Connell has also organized investment partnerships for Aptinyx Inc., (Nasdaq: APTX, IPO 2018), and Naurex Inc. (sold to Allergan, 2015). He holds a BA from Brown University and MBA from the University of Virginia.

Daniel O'Connell

Chief Executive Officer

Jeffrey L. Ives, Ph.D., Consultant

Dan O’Connell has over 20 years of venture creation, venture investment and start-up operations experience. He has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc since December 2014. Mr. O’Connell previously co-founded and served as CEO of Functional NeuroModulation Ltd. (FNM), a company developing implanted deep brain stimulation (DBS) therapies for Alzheimer’s. He led FNM company formation, secured funding of $13.4 million, established a strategic partnership with Medtronic, and recruited an experienced clinical operations team. Under his leadership, FNM initiated and completed enrollment for the ADvance Study, a randomized Phase 2 study of DBS in early AD which is serving as the basis for launching a global Phase 3 study in 2019.

Mr. O’Connell is a founding member and managing partner of NeuroVentures, a specialty venture firm he helped establish in 2001. His NeuroVentures investment and board involvement includes Acumen, BrainCells Inc., Concentric Medical Inc. (sold to Stryker, 2011), Cyberkinetics Inc., Kadmus Pharmaceuticals, Inc. (sold to Schering AG, 2007), NeurAxon Inc., Saegis Pharmaceuticals, Inc. (sold to Lundbeck A/S, 2007), Setagon Inc. (sold to Medtronic, 2007). Mr. O’Connell has also organized investment partnerships for Aptinyx Inc., (Nasdaq: APTX, IPO 2018), and Naurex Inc. (sold to Allergan, 2015). He holds a BA from Brown University and MBA from the University of Virginia.

Jeffrey L. Ives, Ph.D.

Consultant

Daniel O’Connell, Chief Executive Officer

Dan O’Connell has over 20 years of venture creation, venture investment and start-up operations experience. He has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc since December 2014. Mr. O’Connell previously co-founded and served as CEO of Functional NeuroModulation Ltd. (FNM), a company developing implanted deep brain stimulation (DBS) therapies for Alzheimer’s. He led FNM company formation, secured funding of $13.4 million, established a strategic partnership with Medtronic, and recruited an experienced clinical operations team. Under his leadership, FNM initiated and completed enrollment for the ADvance Study, a randomized Phase 2 study of DBS in early AD which is serving as the basis for launching a global Phase 3 study in 2019.

Mr. O’Connell is a founding member and managing partner of NeuroVentures, a specialty venture firm he helped establish in 2001. His NeuroVentures investment and board involvement includes Acumen, BrainCells Inc., Concentric Medical Inc. (sold to Stryker, 2011), Cyberkinetics Inc., Kadmus Pharmaceuticals, Inc. (sold to Schering AG, 2007), NeurAxon Inc., Saegis Pharmaceuticals, Inc. (sold to Lundbeck A/S, 2007), Setagon Inc. (sold to Medtronic, 2007). Mr. O’Connell has also organized investment partnerships for Aptinyx Inc., (Nasdaq: APTX, IPO 2018), and Naurex Inc. (sold to Allergan, 2015). He holds a BA from Brown University and MBA from the University of Virginia.

Daniel O'Connell

Chief Executive Officer

Daniel O’Connell, Chief Executive Officer

Dan O’Connell has over 20 years of venture creation, venture investment and start-up operations experience. He has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc since December 2014. Mr. O’Connell previously co-founded and served as CEO of Functional NeuroModulation Ltd. (FNM), a company developing implanted deep brain stimulation (DBS) therapies for Alzheimer’s. He led FNM company formation, secured funding of $13.4 million, established a strategic partnership with Medtronic, and recruited an experienced clinical operations team. Under his leadership, FNM initiated and completed enrollment for the ADvance Study, a randomized Phase 2 study of DBS in early AD which is serving as the basis for launching a global Phase 3 study in 2019.

Mr. O’Connell is a founding member and managing partner of NeuroVentures, a specialty venture firm he helped establish in 2001. His NeuroVentures investment and board involvement includes Acumen, BrainCells Inc., Concentric Medical Inc. (sold to Stryker, 2011), Cyberkinetics Inc., Kadmus Pharmaceuticals, Inc. (sold to Schering AG, 2007), NeurAxon Inc., Saegis Pharmaceuticals, Inc. (sold to Lundbeck A/S, 2007), Setagon Inc. (sold to Medtronic, 2007). Mr. O’Connell has also organized investment partnerships for Aptinyx Inc., (Nasdaq: APTX, IPO 2018), and Naurex Inc. (sold to Allergan, 2015). He holds a BA from Brown University and MBA from the University of Virginia.

Daniel O'Connell

Chief Executive Officer

Research